We found that EGFR inhibition was synthetically lethal with KRASG12D blockade, as co-targeting KRASG12D and EGFR resulted in more potent cell apoptosis in vitro and tumor shrinkage in vivo (Fig. 7). This evidence concerns the gene EGFR and neoplasm.